NEFL polyclonal antibody
- Known as:
- NEFL pab (anti-)
- Catalog number:
- PAB13723
- Product Quantity:
- 50 uL
- Category:
- -
- Supplier:
- Abno
- Gene target:
- NEFL polyclonal antibody
Related genes to: NEFL polyclonal antibody
- Gene:
- NEFL NIH gene
- Name:
- neurofilament light
- Previous symbol:
- -
- Synonyms:
- NFL, CMT1F, CMT2E, NF68, PPP1R110
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: NEFL polyclonal antibody
Related articles to: NEFL polyclonal antibody
- Individuals with type 2 diabetes (T2D) have increased risk of acute myocardial infarction (AMI). Cardiovascular risk within T2D is heterogeneous and not fully explained by conventional risk factors, highlighting the need for improved biological risk stratification. - Source: PubMed
Publication date: 2026/08/11
Gurung Resham LalZheng HuiliTan Jia Le IvanWu HaoLiu SylviaDorajoo RajkumarLiu Jian-JunLim Su Chi - Subjective cognitive concerns frequently diverge from objective cognitive performance in cognitively unimpaired (CU) older adults, yet the neurobiological basis of this mismatch remains unclear. - Source: PubMed
Wan LuKang ChaeryonHarrison RaeSolis-Urra PatricioSewell Kelsey ROberlin Lauren EJain ShivangiHuang HaiqingGrove GeorgeKamboh M IlyasSutton Bradley PSnitz Beth EKramer Arthur FMcAuley EdwardBurns Jeffrey MHillman Charles HVidoni Eric DMarsland Anna LKarikari Thomas KMorris JillErickson Kirk I - The apolipoprotein E ε4 (APOE ε4) allele confers the greatest genetic risk for sporadic Alzheimer's disease (AD). - Source: PubMed
Publication date: 2026/08/07
Yang Ze-LinZhang CanTang ShiZhang Xin-YuHuang Liang-YuTan Lan - Late-onset unexplained epilepsy (LOUE) represents a substantial proportion of epilepsies with onset after 50 years and often manifests as temporal lobe epilepsy (LO-TLE). Although a link with Alzheimer disease (AD) has been suggested, only a subset of LO-TLE shows AD-related biomarkers, indicating biological heterogeneity. This study aims to characterize the cognitive and CSF phenotype of LO-TLE and compare it with healthy controls (HCs) and patients with mild cognitive impairment due to AD (MCI-AD). - Source: PubMed
Publication date: 2026/08/04
Casarini AlessiaBallerini AliceMaramotti RiccardoTondelli ManuelaCarbone ChiaraChiari AnnalisaVinceti GiuliaBedin RobertaUrbano TeresaMalagoli MarcellaGenovese MaurilioScolastico SimonaGiovannini GiadaPugnaghi MatteoOrlandi NiccolòMolinari Maria AngelaMeletti StefanoZamboni GiovannaVaudano Anna-Elisabetta - Natalizumab (NTZ) is a high-efficacy therapy for relapsing-remitting multiple sclerosis (RRMS) that can be administered intravenously (IV) or subcutaneously (SC). While switching from IV to SC NTZ is increasingly common in clinical practice, evidence on pharmacodynamic stability, particularly under extended interval dosing (6 weeks), remains limited. This study aimed to evaluate CD49d receptor occupancy (RO), serum neurofilament light chain (sNfL) levels, and clinical outcomes in RRMS patients switching from IV to SC NTZ while maintaining either 4- or 6-week dosing intervals. - Source: PubMed
Publication date: 2026/07/22
Agundez-Moreno AlexPresas-Rodríguez SilviaGonzález-García Antonio ManuelTeniente-Serra AinaArcos-Ribas BertaMartínez-Caceres Eva MariaQuerol LuisMartín-Aguilar LorenaVidal-Jordana ÁngelaMeca Lallana Jose EDos-Santos CamilaMillan JorgeValero GabrielCano AntonioCasado VirginiaBoltes-Alandi AnunciaHervas-Garcia Jose VicenteBrieva LuisAlvarez GaryRamo-Tello Cristina